Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastat… (NCT07316439) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer
China197 participantsStarted 2024-12-31
Plain-language summary
This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
* MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2017 and 2023
* Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage
* Contemporaneous patients with metastatic TNBC at initial diagnosis
Exclusion Criteria:
* Patients with incomplete medical records and those diagnosed with secondary primary tumors